Contains A Polypeptide Hormone Patents (Class 435/406)
-
Patent number: 11685899Abstract: The present disclosure relates to methods, cell culture medium and compositions that promote cell proliferation during fetal bovine serum free cell culture.Type: GrantFiled: October 11, 2019Date of Patent: June 27, 2023Assignee: MESOBLAST INTERNATIONAL SARLInventors: Paul Simmons, Colby Suire
-
Patent number: 11396540Abstract: The present invention provides methods and compositions for making proteins, preferably antibodies, more preferably anti-tumor necrosis factor alpha antibodies, and most preferably adalimumab. The present invention further provides methods and compositions for mammalian cell culture, preferably Chinese Hamster Ovary cells.Type: GrantFiled: September 9, 2019Date of Patent: July 26, 2022Assignee: Coherus Biosciences, Inc.Inventor: Elzbieta Wiktoria Puchacz
-
Patent number: 11292829Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures by changing the temperature of the cell culture and/or by starving the cells in their asparagine supply.Type: GrantFiled: June 29, 2012Date of Patent: April 5, 2022Assignee: AMGEN INC.Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
-
Patent number: 10947510Abstract: The invention relates to a method for culturing epithelial stem cells, isolated tissue fragments comprising said epithelial stem cells, or adenoma cells, and culturing the cells or fragments in the presence of a Bone Morphogenetic Protein (BMP) inhibitor, a mitogenic growth factor, and a Wnt agonist when culturing epithelial stem cells and isolated tissue fragments. The invention further relates to a cell culture medium comprising a BMP inhibitor, a mitogenic growth factor, and a Wnt agonist, to the use of said culture medium, and to crypt-villus organoids, gastric organoids and pancreatic organoids that are formed in said culture medium.Type: GrantFiled: November 13, 2013Date of Patent: March 16, 2021Assignee: Koninklijke Nederlandse Akademie Van WetenschappenInventors: Toshiro Sato, Johannes C. Clevers, Meritxell Huch Ortega
-
Patent number: 9663485Abstract: The subject invention relates to improved tocopheryl quinone derivatives and tocopherol derivatives having improved pharmacokinetics in vivo that can, in some embodiments, be useful in the treatment of Lysosomal Storage Disorders, restoration of normal mitochondrial ATP production, modulation of intracellular calcium ion concentration and other treatments or therapies. The tocopheryl quinone derivatives and tocopherol derivatives have side chains that have terminally halogenated carbon atoms.Type: GrantFiled: November 14, 2013Date of Patent: May 30, 2017Assignee: The United States of America, As Presented by The Scretary, Department of Health and Human ServicesInventors: Juan Jose Marugan, Wei Zheng, Jingbo Xiao, John McKew
-
Patent number: 9464275Abstract: Methods are provided for long term culture of mammalian intestinal cells. Cultures are initiated with fragments of mammalian intestinal tissue, which are then maintained embedded in a gel substrate that provides an air-liquid interface. Intestinal epithelium in cultures of the invention can be continuously grown for extended periods of time. Mammalian intestinal cells cultured by the methods of the invention recapitulate features of intestinal growth in vivo.Type: GrantFiled: August 21, 2009Date of Patent: October 11, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Calvin Jay Kuo, Akifumi Ootani
-
Patent number: 9382513Abstract: The present invention relates to a method for producing avian cell lines, comprising gradual or complete withdrawal of growth factors, serum and/or feeder layer so that the established lines are adherent or nonadherent cells capable of proliferating indefinitely in a basic culture medium. The invention also relates to the cells derived from such lines which are particularly useful for the production of substances of interest.Type: GrantFiled: March 3, 2010Date of Patent: July 5, 2016Assignee: ValnevaInventors: Bertrand Pain, Fabienne Guehenneux
-
Patent number: 9359435Abstract: The present invention relates to methods of modulating (e.g., reducing) the mannose content, particularly high-mannose content of recombinant glycoproteins.Type: GrantFiled: January 14, 2013Date of Patent: June 7, 2016Assignee: Amgen Inc.Inventors: Jian Wu, Nicole Le, Michael De La Cruz, Gregory Flynn
-
Patent number: 9260694Abstract: The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from duck embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.Type: GrantFiled: November 1, 2013Date of Patent: February 16, 2016Assignee: ValnevaInventors: Fabienne Guehenneux, Karine Moreau, Magali Esnault, Majid Mehtali
-
Patent number: 9206389Abstract: The present invention relates to a culture including a growth medium and a combination of cytokines consisting of i) interleukin-6 (IL6); ii) flt3-ligand (FLT3); iii) stem cell factor (SCF) and iv) thrombopoi-etin (TPO); the use of the culture for expanding. ex vivo stem cells and/or parental cells and cells differentiated therefrom, and the use of said cells obtainable from said expansion.Type: GrantFiled: July 9, 2008Date of Patent: December 8, 2015Assignee: Fondazione IRCCS Ca' Granda-Ospedale Maggiore PoliclinicoInventors: Lorenza Lazzari, Tiziana Montemurro, Rosaria Giordano, Paolo Rebulla, Girolamo Sirchia
-
Patent number: 9029146Abstract: We disclose a method of preparing a conditioned cell culture medium, the method comprising the steps of: (a) culturing a mesenchymal stem cell (MSC), a descendent thereof or a cell line derived therefrom in a cell culture medium; and (b) optionally isolating the cell culture medium; in which the mesenchymal stem cell (MSC) is obtained by propagating a cell obtained by dispersing a embryonic stem (ES) cell colony, or a descendent thereof, in the absence of co-culture in a serum free medium comprising FGF2.Type: GrantFiled: August 15, 2007Date of Patent: May 12, 2015Assignee: Agency for Science, Technology and ResearchInventors: Sai Kiang Lim, Elias Lye
-
Publication number: 20150119557Abstract: We describe cell culture media for in vitro culture of a human cancer cell of the lymphocyte lineage (e.g., leukemia, lymphoma, or other blasts) or a precursor thereof, especially T-cell acute lymphoblastic leukemia lymphoma (T-ALL), as well as methods for at least maintenance, propagation, or both of the human cancer cell or its precursor.Type: ApplicationFiled: April 12, 2013Publication date: April 30, 2015Applicants: THE UNIVERSITY OF MIAMI, THE BRITISH COLUMBIA CANCER AGENCY BRANCH, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Andrew P. Weng, Jon C. Aster, Tan A. Ince
-
Publication number: 20150072421Abstract: The present invention relates to a method for preparing stem cells having a size suitable for intravascular administration, and preferably to a method for preparing stem cells with a diameter ranging from 11-16 ?m. Additionally, the present invention relates to media composition for preparing stem cells having a size suitable for intravascular administration. According to the present invention, stem cells having a size suitable for intravascular administration can be prepared such that stem cells administered into a vein can stably reach a target tissue, and thus can more efficiently increase efficacy displaying activity, thereby innovatively enhancing the efficacy of cell therapy using stem cells.Type: ApplicationFiled: April 17, 2013Publication date: March 12, 2015Applicants: K-STEMCELL CO., LTD.Inventors: Jeong Chan Ra, Sung Keun Kang, Il Seob Shin
-
Patent number: 8936939Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.Type: GrantFiled: July 23, 2012Date of Patent: January 20, 2015Assignees: Whitehead Institute for Biomedical Research, The Brigham and Women's Hospital, Inc.Inventors: Tan A. Ince, Robert A. Weinberg
-
Publication number: 20140308747Abstract: Methods and kits for expanding the number of hematopoietic stem cells are provided. The methods comprise incubating cells in medium comprising isolated IGFBP-2 and an angiopoietin-like protein (Angptl). Expanded HSCs are provided as well as culture media and kits for the expansion of human HSCs in a defined medium. Methods of administering expanded human HSCs to and individual are provided as well as methods of treating an individual by administering certain growth factors and cytokines.Type: ApplicationFiled: November 12, 2013Publication date: October 16, 2014Applicant: Whitehead Institute for Biomedical ResearchInventors: ChengCheng Zhang, Harvey Lodish
-
Publication number: 20140256044Abstract: This document provides methods and materials involved in creating immortalized cell lines (e.g., immortalized breast, ovarian, or prostate cancer cell lines) and culturing immortalized cell lines. For example, culture media that can be used to create immortalized breast, ovarian, or prostate cancer cell lines are provided.Type: ApplicationFiled: February 26, 2014Publication date: September 11, 2014Inventor: Laura Marlow
-
Patent number: 8822212Abstract: A method for forming at least a tooth root in a tooth containing a tooth crown, including: forming a culture core containing the tooth and a cell-containing base material, the tooth being wrapped with the cell-containing base material, and culturing the culture core in a medium to form at least the tooth root in the tooth contained therein, wherein the cell-containing base material contains at least one kind of cells selected from periodontal ligament-derived cells, bone marrow-derived cells, dental follicle-derived cells, dental pulp-derived cells and dental papilla-derived cells, and the medium contains a component contained in a conditioned medium of a serum-free-cultured cell line of a human uterocervical squamous carcinoma cell line; an additive containing at least one selected from IL-1?, IL-6, IL-8, IL-9, EGF, IGF-I, GH, PDGF-AB, VEGF, LIF, HGF, FGF-2, FGF-1, BMP-2, BMP-4, M-CSF, dexamethasone, insulin, thyroxine, thyrocalcitonin, ascorbic acid and ?-glycerophosphate; or both of them.Type: GrantFiled: March 4, 2011Date of Patent: September 2, 2014Assignee: The Nippon Dental UniversityInventors: Taka Nakahara, Hiroshi Ishikawa, Soh Sato, Masato Ohta
-
Patent number: 8815588Abstract: We disclose a method of preparing a conditioned cell culture medium, the method comprising the steps of: (a) culturing a mesenchymal stem cell (MSC), a descendent thereof or a cell line derived therefrom in a cell culture medium; and (b) optionally isolating the cell culture medium; in which the mesenchymal stem cell (MSC) is obtained by propagating a cell obtained by dispersing a embryonic stem (ES) cell colony, or a descendent thereof, in the absence of co-culture in a serum free medium comprising FGF2.Type: GrantFiled: August 15, 2007Date of Patent: August 26, 2014Assignee: Agency for Science, Technology and ResearchInventors: Sai Kiang Lim, Elias Lye
-
Publication number: 20140178987Abstract: The present invention discloses a stem cell culture medium and its applications as well as a stem cell culture method. The said stem cell culture medium contains no serum. The said stem cell culture medium contains amino acids, vitamins, salts, lipids, cytokines and protein polypeptides. The said stem cell culture medium is suitable for rapid culture of stem cells derived from human and mammalian tissues, including but not limited to, adipose mesenchymal stem cells, bone marrow mesenchymal stem cells and umbilical cord blood stem cells. The said culture medium can increase the proliferation speed of the stem cells 3-5 times, without any affects on their differentiation potentials. Comparing the said stem cell culture medium to a routine culture medium, the said culture medium is not only able to proliferate stem cells derived from different sources more rapidly and achieve more proliferation generations, but also keep their differentiation potentials well.Type: ApplicationFiled: January 31, 2013Publication date: June 26, 2014Inventors: Xiaoqing Liu, Ming Ying, Guangfeng Chen, Longpo Zheng
-
Publication number: 20140170748Abstract: This invention provides for methods of growing anchorage-dependent cells (e.g. hUTC) in culture medium comprising amino acids, vitamins, salts nucleosides, insulin, transferrin, ethanolamine and sodium selenium, wherein the culture medium is supplemented with serum. The method further comprises addition of a serum-free nutrient solution comprising amino acids, vitamins, salts nucleosides, insulin, transferrin, ethanolamine and sodium selenium. The invention also provides for culture media and serum-free nutrient solutions for growing anchorage-dependent cells.Type: ApplicationFiled: December 14, 2012Publication date: June 19, 2014Applicant: DePuy Synthes Products, LLCInventors: Ravinder Bhatia, L.S. Klaudyne Hong, Sadettin S. Ozturk, Venkat Haricharan Kamaraju
-
Patent number: 8700513Abstract: Transaction processing involves receiving data from an access transaction application of a portable consumer device, wherein the received data comprises data from an access transaction data string that includes a transit verification value wherein, with the exception of the transit verification value, the access transaction data string is substantially similar to a retail data string comprising retail data, wherein the access application data string is adapted for use with an access transaction processing system and the retail data string is adapted for use with a retail processing system. The transaction processing involves processing access transaction application data for selective authorization of the transaction.Type: GrantFiled: November 30, 2012Date of Patent: April 15, 2014Assignee: Visa U.S.A. Inc.Inventors: Ayman Hammad, Philip B. Dixon
-
Publication number: 20140073053Abstract: The present disclosure provides culture media and methods of using culture media for efficient transfection of a target cell with nucleic acid molecules. The media is capable of supporting cells in culture that are differentiating, transdifferentiating, and/or dedifferentiating.Type: ApplicationFiled: September 6, 2013Publication date: March 13, 2014Applicant: Massachusetts Institute of TechnologyInventors: Mehmet Fatih Yanik, Matthew Angel
-
Patent number: 8663945Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.Type: GrantFiled: November 30, 2011Date of Patent: March 4, 2014Assignee: AbbVie IncInventors: Itzcoatl A. Pla, Joseph C. Matuck, John C. Fann, Christof Schulz, Nicole A. Roy, David F. Bruton, James McIntire, David Chang Yu-Hsiang, Thomas Seewoester
-
Publication number: 20140057353Abstract: An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided. A method of producing hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises expanding hematopoietic stem cells by culturing hematopoietic stem cells ex vivo in the presence of a compound represented by the formula following (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof (wherein R1 to R8 are as defined in the description).Type: ApplicationFiled: December 1, 2011Publication date: February 27, 2014Applicants: REPROCELL INCORPORATED, NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Ayako Asai, Taito Nishino, Makiko Yui
-
Patent number: 8642339Abstract: The invention relates to a method for culturing epithelial stem cells, isolated tissue fragments comprising the epithelial stem cells, or adenoma cells, and culturing the cells or fragments in the presence of a Bone Morphogenetic Protein (BMP) inhibitor, a mitogenic growth factor, and a Wnt agonist when culturing epithelial stem cells and isolated tissue fragments. The invention further relates to a cell culture medium comprising a BMP inhibitor, a mitogenic growth factor, and a Wnt agonist, to the use of the culture medium, and to crypt-villus organoids, gastric organoids and pancreatic organoids that are formed in the culture medium.Type: GrantFiled: February 3, 2010Date of Patent: February 4, 2014Assignee: Koninklijke Nederlandse Akademie van WetenschappenInventors: Toshiro Sato, Johannes Carolus Clevers
-
Publication number: 20140031294Abstract: The present invention provides a recombinant protein comprising the sequence of a transferrin mutant, wherein Ser415 is mutated to an amino acid which does not allow glycosylation at Asn413 and/or wherein Thr613 is mutated to an amino acid which does not allow glycosylation as Asn611. It also provides polynucleotides encoding the same and methods of making and using said recombinant protein.Type: ApplicationFiled: July 29, 2013Publication date: January 30, 2014Applicant: Novozymes Biopharma DK A/SInventors: Christopher John Arthur Finnis, Darrell Sleep, Joanna Hay
-
Patent number: 8617889Abstract: Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are disclosed and claimed. In addition, methods, compositions, and kits for forming coronary vasculature including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are described. In particular, administration of variants of hepatocyte growth factor, such as NK1, 1K1, and HP11, are useful for the repair and/or regeneration of damaged myocardium or formation of coronary vasculature. Methods of activating cardiac stem cells in vitro are also disclosed.Type: GrantFiled: July 17, 2012Date of Patent: December 31, 2013Assignee: New York Medical CollegeInventor: Piero Anversa
-
Publication number: 20130236973Abstract: The present invention provides methods to promote the proliferation of undifferentiated pluripotent stem cells in defined media. Specifically, the invention provides a defined cell culture formulation for the culture, maintenance, and expansion of pluripotent stem cells, wherein culturing stem cells in the defined cell culture formulation maintains the pluripotency and karyotypic stability of the cells for at least 10 passages. Further disclosed is a cell population grown under defined media conditions that express OCT4, SOX2, NANOG, and FOXA2.Type: ApplicationFiled: March 6, 2013Publication date: September 12, 2013Applicant: JANSSEN BIOTECH, INC.Inventor: Alireza Rezania
-
Publication number: 20130236430Abstract: Those provided here are an Activin A-containing solution for making inhibitory neuron progenitors proliferate, a method for culturing the inhibitory neuron progenitors using this solution, a method for separating the inhibitory neuron progenitors and the inhibitory neurons using an Activin A receptor Acvr1 expression as an index, a method for transplanting thus separated cells to the brain surface, and a method for screening a factor for making the inhibitory neuron progenitors proliferate.Type: ApplicationFiled: September 22, 2011Publication date: September 12, 2013Inventors: Nobuaki Tamamaki, Shengx Wu, Shogo Ninomiya
-
Publication number: 20130164839Abstract: The present invention is directed to providing a method for culturing cells in a system containing laminin-5. The method of the present invention is characterized by a culture system containing a polypeptide selected from a group consisting of: a protein in blood other than extracellular matrix proteins, which is, serum, serum albumin, prealbumin, immunoglobulin, ?-globulin, ?-globulin, ?1-antitrypsin (?1-AT), heptoglobin (Hp), ?2-macroglobulin (?2-M), ?-fetoprotein (AFP), transferrin, retinol-binding protein (RBP) or adiponectin; gelatin; a protein belonging to a tumor necrosis factor (TNF) family; and peptone.Type: ApplicationFiled: March 31, 2011Publication date: June 27, 2013Applicant: ORIENTAL YEAST CO., LTD.Inventors: Hisataka Yasuda, Munehiro Yamada, Yukiko Taketani, Yoshiya Tomimori, Kaoru Mori
-
Publication number: 20130130373Abstract: The present disclosure relates, in general to a kit comprising a serum replacement and one or more labile factors, such as growth factors, packaged separately in the kit. It is contemplated that the kit provides advantages to improve cell growth in culture compared to cells cultured not using the kit described herein.Type: ApplicationFiled: November 9, 2012Publication date: May 23, 2013Applicant: ESSENTIAL PHARMACEUTICALS, LLCInventor: Essential Pharmaceuticals, LLC
-
Patent number: 8426203Abstract: Previous methods for culturing primate pluripotent stem cells have required either fibroblast feeder cells or a medium which was exposed to fibroblast feeder cells to maintain the stem cells in an undifferentiated state. It has now been found that high levels of fibroblast growth factor in a medium together with at least one of gamma aminobutyric acid, pipecolic acid, and lithium, enables pluripotent stem cells to remain undifferentiated indefinitely through multiple passages, even without feeder cells or conditioned medium. Without beta-mercaptoethanol, the medium improves cloning efficiency. Also, a matrix of human proteins can be used to culture the undifferentiated cells without exposing the cells to animal products. Further disclosed are new primate pluripotent cell lines made using the defined culture conditions, including the medium and the matrix. Such new cell lines will have never been exposed to animal cells, animal products, feeder cells or conditioned medium.Type: GrantFiled: March 22, 2012Date of Patent: April 23, 2013Assignee: Wisconsin Alumni Research FoundationInventors: James A. Thomson, Tenneille Ludwig
-
Publication number: 20130089928Abstract: Embodiments of chemically defined cell culture media containing nutrients and growth factors free of any serum for culturing cells such as mesenchymal stem cells and methods of using embodiments of the cell culture medium for expanding cell populations such as mesenchymal stem cells while maintaining a pluripotent phenotype and methods of inducing chondrogenesis and osteogenesis of mesenchymal stem cells by admixing differentiation factors into embodiments of the cell culture medium.Type: ApplicationFiled: June 16, 2011Publication date: April 11, 2013Inventors: Songzhu An, Yanan Zhu
-
Publication number: 20130071834Abstract: The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.Type: ApplicationFiled: June 29, 2012Publication date: March 21, 2013Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Ann Kwong, Randal Byrn, Lola M. Reid
-
Publication number: 20130040390Abstract: The present invention provides a chemically defined culture system, by which induced pluripotent stem (iPS) cells are obtained with high efficiency. The culture medium supplement of the present invention includes vitamin C and a glycogen synthase kinase-3 inhibitor; another culture medium supplement of the present invention further includes, in addition to vitamin C and the glycogen synthase kinase-3 inhibitor, vitamin B12, insulin, a receptor tyrosine kinase, and an anti-oxidant; and the culture medium supplement of the present invention may further be a mixture of the above two culture medium supplements with a serum replacement cell growth promoter. The present invention further provides a complete culture medium for iPS cells, which is formed by one or more of a basal culture medium, serum, and a serum replacement supplement, and the above culture medium supplements, or formed only by the above culture medium supplements and a basal culture medium.Type: ApplicationFiled: July 29, 2010Publication date: February 14, 2013Applicant: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCEInventors: Duanqing Pei, Jiekai Chen, Jing Liu
-
Publication number: 20120329087Abstract: A cell preparation containing mesenchymal stem cells whose immunosuppression ability is maintained is produced by means of a serum-free or low-serum culture. A method for producing a cell preparation containing mesenchymal stem cells, comprising the steps of: (A) proliferating mesenchymal stem cells in a serum-free medium “A” containing an FGF, a PDGF, a TGF-?, an HGF, an EGF, at least one phospholipid, and at least one fatty acid; and (B) screening mesenchymal stem cells whose immunosuppression ability is maintained or improved, from the mesenchymal stem cells thus proliferated in the step (A).Type: ApplicationFiled: March 10, 2011Publication date: December 27, 2012Applicant: TWO CELLS CO., LTD.Inventors: Toshie Tsuchiya, Koichiro Tsuji, Yukio Kato, Jin Chang Shao, Maiko Hara
-
Publication number: 20120315697Abstract: The present invention relates to cell culture media containing combinations of proteins, as well as methods of making the cell culture media, and methods of using the cell culture media to improve growth characteristics of cultured cells.Type: ApplicationFiled: February 18, 2010Publication date: December 13, 2012Applicant: VENTRIA BIOSCIENCEInventors: Steven Clyde Pettit, Mary Ann Michelle Fernandez Santos, Ning Huang
-
Patent number: 8329466Abstract: The present invention relates to a method for the cultivation of primary cells. The primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The method for the cultivation of primary cells may be one step in a method for the amplification of viruses, such as poxviruses. According to this latter method the primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The cells are then infected with the virus and the infected cells are cultivated in serum free medium until progeny virus is produced.Type: GrantFiled: May 12, 2011Date of Patent: December 11, 2012Assignee: Bavarian Nordic A/SInventors: Ingmar Rathe, Eva Felder, Karl Heller
-
Publication number: 20120294949Abstract: Methods of producing stem cell conditioned media to treat mammalian injuries or insults. In at least one embodiment of a method of producing a stem cell conditioned media of the present disclosure, the method comprises the steps of culturing at least one stem cell in a first cell culture medium, replacing some or all of the first cell culture medium with a second cell culture medium and further culturing the at least one stem cell in the second cell culture medium, and collecting a quantity of the second cell culture medium after a culture duration, wherein the quantity of the second cell culture medium contains a cell culture byproduct effective to treat a mammalian insult or injury. In another embodiment, the step of culturing comprises culturing the at least one stem cell in EGM2MV.Type: ApplicationFiled: May 22, 2012Publication date: November 22, 2012Inventors: Brian H. Johnstone, Keith Leonard March, Yansheng Du
-
Publication number: 20120270319Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: ApplicationFiled: October 6, 2011Publication date: October 25, 2012Inventors: Diana L. Clarke, Charlotte A. Smith, Richard A. Banas, Vivienne S. Marshall
-
Publication number: 20120258538Abstract: By culturing hematopoietic stem cells in the presence of SFRP-F protein, hematopoietic stem cells for hematopoietic stem cell transplantation can be produced.Type: ApplicationFiled: September 9, 2010Publication date: October 11, 2012Applicant: Keio UniversityInventor: Hideaki Nakajima
-
Publication number: 20120230940Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.Type: ApplicationFiled: March 9, 2012Publication date: September 13, 2012Applicant: SkinMedica. Inc.Inventors: Gail K. Naughton, David L. Horwitz, Mark A. Applegate, Joan Zeltinger, Jonathan N. Mansbridge, Andreas Kern, Lee K. Landeen, Anthony Ratcliffe, R. Emmett Pinney
-
Patent number: 8252591Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.Type: GrantFiled: May 6, 2005Date of Patent: August 28, 2012Assignees: Whitehead Institute for Biomedical Research, The Brigham and Women's HospitalInventors: Tan A. Ince, Robert A. Weinberg
-
Publication number: 20120202291Abstract: Fully defined media that support pluripotent cell viability, proliferation, cloning, and derivation, as well as methods and compositions including these media are described. Methods for deriving iPS cells from adult individuals under defined, xeno-free conditions are also described.Type: ApplicationFiled: August 5, 2011Publication date: August 9, 2012Inventors: Guokai Chen, James A. Thomson
-
Publication number: 20120088299Abstract: Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hamiones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.Type: ApplicationFiled: November 2, 2011Publication date: April 12, 2012Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Zhengxing Qu, Chien-Hsing Chang, Edmund A. Rossi, Jeng-Dar Yang, Diane Nordstrom
-
Publication number: 20120077213Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.Type: ApplicationFiled: November 30, 2011Publication date: March 29, 2012Applicant: Abbott LaboratoriesInventors: Itzcoatl A. Pla, Joseph G. Matuck, John C. Fann, Christof Schulz, Nichole A. Roy, David F. Bruton, James McIntire, Yu-Hsiang David Chang, Thomas Seewoester
-
Patent number: 8138147Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and/or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder.Type: GrantFiled: January 6, 2009Date of Patent: March 20, 2012Assignee: Skinmedica, Inc.Inventors: Gail K. Naughton, David L. Horwitz, Mark A. Applegate, Joan Zeltinger, Jonathan N. Mansbridge, Andreas Kern, Lee K. Landeen, Anthony Ratcliffe, R. Emmett Pinney
-
Publication number: 20120052577Abstract: The present invention provides methods and compositions for culturing stem cells, such as neural stem cells, and includes inducing the specification of neural stem cells to the oligodendrocyte phenotype and specification of multipotent cells ie. iPS cells and ES cells.Type: ApplicationFiled: August 31, 2011Publication date: March 1, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Maria Dolores Araceli Espinosa de los Monteros, Jean S. de Vellis
-
Publication number: 20120028355Abstract: The invention relates to a method for culturing epithelial stem cells, isolated tissue fragments comprising the epithelial stem cells, or adenoma cells, and culturing the cells or fragments in the presence of a Bone Morphogenetic Protein (BMP) inhibitor, a mitogenic growth factor, and a Wnt agonist when culturing epithelial stem cells and isolated tissue fragments. The invention further relates to a cell culture medium comprising a BMP inhibitor, a mitogenic growth factor, and a Wnt agonist, to the use of the culture medium, and to crypt-villus organoids, gastric organoids and pancreatic organoids that are formed in the culture medium.Type: ApplicationFiled: February 3, 2010Publication date: February 2, 2012Applicant: Koninklijke Nederlandse Akademie van WetenschappenInventors: Toshiro Sato, Johannes Carolus Clevers, Meritxell Huch Ortega
-
Publication number: 20120028353Abstract: The present invention relates to precursor cells to hepatic stellate cells, compositions comprising same and methods of isolating same. The surface antigenic profile of the precursors is MHC class Ia negative, ICAM-1+, VCAM-1+, ?3-integrin+. In addition to expression of these surface markers, the cells also express the intracellular markers desmin, vimentin, smooth muscle ?-actin, nestin, hepatocyte growth factor, stromal derived factor-1? and Hlx homeobox transcriptional factor.Type: ApplicationFiled: October 13, 2010Publication date: February 2, 2012Inventors: Hiroshi Kubota, Lola M. Reid